Inquire About a Product| Product: | Everolimus | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalog Number: | 10192 | ||||||||||||
| CAS Number: | 159351-69-6 | ||||||||||||
| Synonyms: |
42-O-(2-Hydroxyethyl)rapamycin; RAD-001; SDZRAD; Certican |
||||||||||||
| Pricing: |
|
||||||||||||
| Formula: | C53H83NO14 | ||||||||||||
| Chemical Purity: | 99.6% | ||||||||||||
| Molecular Weight: | 958.22 | ||||||||||||
| Structure: |
|
||||||||||||
| Appearance: | White to faintly yellow powder | ||||||||||||
| Category: | All Inhibitors | ||||||||||||
| Stability: | Stable under recommended storage conditions. | ||||||||||||
| Storage: |
Recommended storage temperature: -15 °C, in dry environment, protected from light. |
||||||||||||
| Transportation: |
Non-hazardous for transport |
||||||||||||
| Literature References: |
Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S., Grunwald, V., Thompson, J.A., FIglin, R.A., Hollaender, N., Urbanowitz, G., Berg, W.J., Kay, A., Lebwohl, D., Ravaud, A., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet, 2008, 372(9637):449-456.; Yao, J.C., et al., Everolimus for Advanced Pancreatic Neuroendocrine Tumors. The New England Journal of Medicine, 2011, 364:514-523. |
||||||||||||
| MSDS: | |||||||||||||
| Applications: | An inhibitor of mammalian target of rapamycin. Used as an immunosuppressant to prevent organ transplant rejection. Also used as a treatment of renal cell cancer and other tumors. |